Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis

Joint Bone Spine

Volumn 81, Issue 1, 2014, Pages 6-14

  Wendling, Daniel ^a   Lukas, Cédric ^b   Paccou, Julien ^c,d   Claudepierre, Pascal ^e,f   Carton, Laurence ^g   Combe, Bernard ^b   Goupille, Philippe ^h   Guillemin, Francis ⁱ   Hudry, Christophe ^j   Miceli Richard, Corinne ^k   Dougados, Maxime ^l  

^a CHRU de Besançon ^*  (France)

^b LAPEYRONIE HOSPITAL   (France)

^c AMIENS UNIVERSITY HOSPITAL   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f Hpital Henri Mondor   (France)

^g Association Karu Asthme   (France)

^h UNIVERSITÉ DE TOURS   (France)

ⁱ UNIVERSITY HOSPITAL OF NANCY   (France)

^j Cabinet de Rhumatologie   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Ankylosing spondylitis; NSAIDs; Physiotherapy; Rehabilitation; Spondyloarthritis; Therapeutic education; TNF antagonists; Treatment

Indexed keywords

ANALGESIC AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; APREMILAST; BETAMETHASONE; DRUG ANTIBODY; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; SALAZOSULFAPYRIDINE; SECUKINUMAB; USTEKINUMAB;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTHROPLASTY; ARTICLE; BATH ANKYLOSING SPONDYLITIS FUNCTIONAL INDEX; BONE MARROW EDEMA; DISEASE ACTIVITY; DISEASE CLASSIFICATION; HEALTH ASSESSMENT QUESTIONNAIRE; HEALTH CARE COST; HUMAN; LABORATORY TEST; MEDICAL HISTORY; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOTOMY; PATIENT EDUCATION; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; REHABILITATION; REMISSION; SACROILIAC JOINT; SMOKING CESSATION; SPONDYLARTHRITIS; ARTHRITIS, PSORIATIC; MEDICAL RESEARCH; BIOLOGICAL THERAPY; DRUG THERAPY; EDUCATION PROGRAM; FOLLOW UP; HEALTH EDUCATION; META ANALYSIS (TOPIC); PATIENT CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION CARE; TREATMENT INDICATION;

ARTHRITIS, PSORIATIC; BIOMEDICAL RESEARCH; HUMANS; SPONDYLARTHRITIS;

EID: 84893748631     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2013.12.002     Document Type: Article

References (86)

1. Braun J., van den Berg R., Baraliakos X., et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011, 70:896-904.
2. van der Heijde D., Sieper J., Maksymowych W.P., et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011, 70:905-908.
3. Brouwers M.C., Kho M.E., Browman G.P., et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010, 182:E839-E842.
4. Dougados M., Betteridge N., Burmester G.R., et al. EULAR standardised operating procedures for the elaboration, evaluation, dissemination, and implementation of recommendations endorsed by the EULAR standing committees. Ann Rheum Dis 2004, 63:1172-1176.
5. van den Berg R., Baraliakos X., Braun J., et al. First update of the current evidence for the management of ankylosing spondylitis with non-pharmacological treatment and non-biologic drugs: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Rheumatology (Oxford) 2012, 51:1388-1396.
6. Baraliakos X., van den Berg R., Braun J., et al. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology (Oxford) 2012, 51:1378-1387.
7. Gossec L., Smolen J.S., Gaujoux-Viala C., et al. European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012, 71:4-12.
8. Ash Z., Gaujoux-Viala C., Gossec L., et al. A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 2012, 71:319-326.
9. Pham T., Fautrel B., Dernis E., et al. Recommendations of the French society for rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007, 74:638-646.
10. Pham T., Bachelez H., Berthelot J.M., et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011, 78:15-185.
11. Smolen J.S., Braun J., Dougados M., et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014, 73:6-16.
12. Schoels M.M., Braun J., Dougados M., et al. Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. Ann Rheum Dis 2013, [Epub ahead of print].
13. Rudwaleit M., van der Heijde D., Landewé R., et al. The development of Assessment of SpondyloArthritis International Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009, 68:777-783.
14. Rudwaleit M., van der Heijde D., Landewé R., et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011, 70:25-31.
15. Sieper J., Rudwaleit M., Baraliakos X., et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009, 68:ii1-ii44.
16. Claudepierre P., Wendling D., Breban M., et al. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name?. Joint Bone Spine 2012, 79:534-535.
17. Wendling D., Prati C., Claudepierre P., et al. Non-radiographic spondyloarthritis: a theoretical concept or a real entity?. Joint Bone Spine 2012, 79:531-533.
18. Berthelot J.M., Le Goff B., Maugars Y. Overdiagnosing early spondyloarthritis: what are the risks?. Joint Bone Spine 2013, 80:446-448. 10.1016/j.jbspin.2013.04.010.
19. Rudwaleit M., Jurik A.G., Hermann K.G., et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009, 68:1520-1527.
20. Prati C., Claudepierre P., Pham T., et al. Mortality in spondylarthritis. Joint Bone Spine 2011, 78:466-470.
21. Bakland G., Gran J.T., Nossent J.C. Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 2011, 70:1921-1925.
22. Bakland G., Gran J.T., Becker-Merok A., et al. Work disability in patients with ankylosing spondylitis in Norway. J Rheumatol 2011, 38:479-484.
23. Wendling D., Claudepierre P., Prati C. Early diagnosis and management are crucial in spondyloarthritis. Joint Bone Spine 2013, 80:582-585.
24. Machado P., Landewé R., Lie E., et al. Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70:47-53.
25. Wendling D., Prati C. Spondyloarthritis and smoking: towards a new insight into the disease. Expert Rev Clin Immunol 2013, 9:511-516.
26. Sudre A., Figuereido I.T., Lukas C., et al. On the impact of a dedicated educational program for ankylosing spondylitis: effect on patient satisfaction, disease knowledge and spinal mobility, a pilot study. Joint Bone Spine 2012, 79:99-100.
27. Eppeland S.G., Diamantopoulos A., Soldal D.M., et al. Short-term in patient rehabilitation in axial spondyloarthritis - the results of a 2-week program performed in daily clinical practice. BMC Res Notes 2013, 6:185.
28. Kjeken I., Bø I., Rønningen A., et al. A three-week multidisciplinary in patient rehabilitation programme had positive long-term effects in patients with ankylosing spondylitis: randomized controlled trial. Rehabil Med 2013, 45:260-267.
29. Ciprian L., Lo Nigro A., Rizzo M., et al. The effects of combined spa therapy and rehabilitation on patients with ankylosing spondylitis being treated with TNF-inhibitors. Rheumatol Int 2013, 33:241-245.
30. Aytekin E., Caglar N.S., Ozgonenel L., et al. Home-based exercise therapy in patients with ankylosing spondylitis: effects on pain, mobility, disease activity, quality of life, and respiratory functions. Clin Rheumatol 2012, 31:91-97.
31. Altan L., Korkmaz N., Dizdar M., et al. Effect of pilates training on people with ankylosing spondylitis. Rheumatol Int 2012, 32:2093-2099.
32. Staalesen Strumse Y.A., Nordvåg B.Y., Stanghelle J.K., et al. Efficacy of rehabilitation for patients with ankylosing spondylitis: comparison of a four-week rehabilitation programme in a Mediterranean and a Norwegian setting. J Rehabil Med 2011, 43:534-542.
33. Masiero S., Bonaldo L., Pigatto M., et al. Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol 2011, 38:1335-1342.
34. van der Horst-Bruinsma I.E., Nurmohamed M.T., Landewé R.B. Co-morbidities in patients with spondyloarthritis. Rheum Dis Clin North Am 2012, 38:523-538.
35. van der Weijden M.A., Claushuis T.A., Nazari T., et al. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol 2012, 31:1529-1535.
36. Klingberg E., Geijer M., Göthlin J., et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol 2012, 39:1987-1995.
37. Del Puente A., Esposito A., Parisi A., et al. Osteoporosis and psoriatic arthritis. J Rheumatol Suppl 2012, 89:36-38.
38. Klingberg E., Lorentzon M., Mellström D., et al. Osteoporosis in ankylosing spondylitis -prevalence, risk factors and methods of assessment. Arthritis Res Ther 2012, 14:R108.
39. Escalas C., Trijau S., Dougados M. Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology 2010, 49:1317-1325.
40. Benhamou M., Gossec L., Dougados M. Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein. Rheumatology (Oxford) 2010, 49:536-541.
41. Wendling D. Do non-steroidal anti-inflammatory drugs have disease-modifying effects in spondyloarthritis?. Joint Bone Spine 2013, 80:563-564.
42. Trelle S., Reichenbach S., Wandel S., et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011, 342:c7086.
43. Coxib and traditional NSAID Trialists' (CNT) Collaboration Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet 2013, [doi:pii: S0140-6736(13)60900-9].
44. Ramiro S., Radner H., van der Heijde D., et al. Combination therapy for pain management in inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 2011, CD008886.
45. Huang Z., Cao J., Li T., et al. Efficacy and safety of ultrasound-guided local injections of etanercept into entheses of ankylosing spondylitis patients with refractory Achilles enthesitis. Clin Exp Rheumatol 2011, 29:642-649.
46. Haibel H., Fendler C., Listing J., et al. Efficacy of oral prednisolone in active ankylosing spondylitis: results of a double-blind, randomised, placebo-controlled short-term trial. Ann Rheum Dis 2013, [Epub ahead of print].
47. Chen J., Veras M.M., Liu C., et al. Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 2013, 2:CD004524.
48. Song I.H., Hermann K., Haibel H., et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011, 70:590-596.
49. Braun J., van der Horst-Bruinsma I.E., Huang F., et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011, 63:1543-1551.
50. Braun J., Pavelka K., Ramos-Remus C., et al. Clinical efficacy of etanercept versus sulfasalazine in ankylosing spondylitis subjects with peripheral joint involvement. J Rheumatol 2012, 39:836-840.
51. Kingsley G.H., Kowalczyk A., Taylor H., et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012, 51:1368-1377.
52. Dougados M. Methotrexate in peripheral spondyloarthritis including psoriatic arthritis: a need for further evaluation. Rheumatology (Oxford) 2012, 51:1343-1344.
53. Goeb V., Ardizzone M., Arnaud L., et al. Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française. Joint Bone Spine 2013, 80:574-581.
54. Arends S., van der Veer E., Kallenberg C.G., et al. Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 2012, 24:290-298.
55. Ottaviani S., Allanore Y., Tubach F., et al. Body mass index influences the response to infliximab in ankylosing spondylitis. Arthritis Res Ther 2012, 14:R115.
56. di Minno M.N., Peluso R., Iervolino S., et al. Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis. Arthritis Care Res (Hoboken) 2013, 65:141-147.
57. Machado M.A., Barbosa M.M., Almeida A.M., et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int 2013, 33:2199-2213.
58. Dougados M., Combe B., Braun J., et al. A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 2010, 69:1430-1435.
59. Dougados M., Braun J., Szanto S., et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford) 2012, 51:1687-1696.
60. Mulleman D., Lauféron F., Wendling D., et al. Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study. Arthritis Res Ther 2011, 13:R82.
61. Fagerli K.M., Lie E., van der Heijde D., et al. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:123-127.
62. Plasencia C., Pascual-Salcedo D., Nuño L., et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012, 71:1955-1960.
63. Dougados M., Simon P., Braun J., et al. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 2011, 70:249-251.
64. Haroon N., Inman R.D., Learch T.J., et al. The impact of tumor necrosis factor (inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 2013, 65:2645-2654.
65. Sterry W., Ortonne J.P., Kirkham B., et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double-blind multicentre trial. BMJ 2010, 340:c147.
66. Navarro-Sarabia F., Fernández-Sueiro J.L., Torre-Alonso J.C., et al. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double-blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 2011, 50:1828-1837.
67. Mulleman D., Ducourau E., Paintaud G., et al. Should anti-TNF-α drug levels and/or anti-drug antibodies be assayed in patients treated for rheumatoid arthritis?. Joint Bone Spine 2012, 79:109-112.
68. Glintborg B., Ostergaard M., Krogh N.S., et al. Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor αinhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 2013, 72:1149-1155.
69. Paccou J., Solau-Gervais E., Houvenagel E., et al. Efficacy in current practice of switching between anti-tumour necrosis factor-α agents in spondyloarthropathies. Rheumatology (Oxford) 2011, 50:714-720.
70. Glintborg B., Ostergaard M., Krogh N.S., et al. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013, 65:1213-1223.
71. Paccou J., Baclé-Boutry M.A., Solau-Gervais E., et al. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice. J Rheumatol 2012, 39:1418-1423.
72. Navarro-Compán V., Moreira V., Ariza-Ariza R., et al. Low doses of etanercept can be effective in ankylosing spondylitis patients who achieve remission of the disease. Clin Rheumatol 2011, 30:993-996.
73. Wendling D., Prati C., Goupille P., et al. Optimizing TNFα antagonist therapy in patients with spondyloarthritis: why and how?. Joint Bone Spine 2011, 78:225-227.
74. Wendling D. Are there new emerging drugs for ankylosing spondylitis or spondyloarthritis?. Expert Opin Emerg Drugs 2013, 18:5-7.
75. Song I.H., Heldmann F., Rudwaleit M., et al. Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 2011, 70:1108-1110.
76. Song I.H., Heldmann F., Rudwaleit M., et al. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 2010, 62:1290-1297.
77. Song I.H., Heldmann F., Rudwaleit M., et al. One-year follow-up of ankylosing spondylitis patients responding to rituximab treatment and re-treated in case of a flare. Ann Rheum Dis 2013, 72:305-306.
78. Wendling D., Dougados M., Berenbaum F., et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French Society of Rheumatology. J Rheumatol 2012, 39:2327-2331.
79. Lekpa F.K., Poulain C., Wendling D., et al. Is IL-6 an appropriate target to treat spondyloarthritis patients refractory to anti-TNF therapy? A multicentre retrospective observational study. Arthritis Res Ther 2012, 14:R53.
80. Sieper J., Porter-Brown B., Thompson L., et al. Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 2013, [Epub ahead of print].
81. Baeten D., Baraliakos X., Braun J., et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 2013, 382:1705-1713.
82. McInnes I.B., Sieper J., Braun J., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 2013, [Epub ahead of print].
83. McInnes I.B., Kavanaugh A., Gottlieb A.B., et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1-year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013, 382:780-789.
84. Schett G., Wollenhaupt J., Papp K., et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64:3156-3167.
85. Pathan E., Abraham S., Van Rossen E., et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis. Ann Rheum Dis 2013, 72:1475-1480. 10.1136/annrheumdis-2012-201915.
86. Vander Cruyssen B., Vastesaeger N., Collantes-Estévez E. Hip disease in ankylosing spondylitis. Curr Opin Rheumatol 2013, 25:448-454.